Article
Regeneron allays competition fears for 'gold standard' eye drug, shares rise
Rating:
0.0
Views:
71
Likes:
1
Library:
1
Regeneron Pharmaceuticals said on Wednesday it expects demand for blockbuster eye drug Eylea to remain strong in the third quarter even in the face of emerging competition from rival drugs, sending the company's shares up nearly 8%.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value